Related Experiment Video
Updated: Jul 12, 2025

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Heterogeneity in the Metastatic Microenvironment: JunB-Expressing Microglia Cells as Potential Drivers of Melanoma
Orit Adir1, Orit Sagi-Assif1, Tsipi Meshel1
1The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 6997801, Israel.
Abstract:
Reciprocal signaling between melanoma brain metastatic (MBM) cells and microglia reprograms the phenotype of both interaction partners, including upregulation of the transcription factor JunB in microglia. Here, we aimed to elucidate the impact of microglial JunB upregulation on MBM progression. For molecular profiling, we employed RNA-seq and reverse-phase protein array (RPPA). To test microglial JunB functions, we generated microglia variants stably overexpressing JunB (JunBhi) or with downregulated levels of JunB (JunBlo). Melanoma-derived factors, namely leukemia inhibitory factor (LIF), controlled JunB upregulation through Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling. The expression levels of JunB in melanoma-associated microglia were heterogeneous. Flow cytometry analysis revealed the existence of basal-level JunB-expressing microglia alongside microglia highly expressing JunB. Proteomic profiling revealed a differential protein expression in JunBhi and JunBlo cells, namely the expression of microglia activation markers Iba-1 and CD150, and the immunosuppressive molecules SOCS3 and PD-L1. Functionally, JunBhi microglia displayed decreased migratory capacity and phagocytic activity. JunBlo microglia reduced melanoma proliferation and migration, while JunBhi microglia preserved the ability of melanoma cells to proliferate in three-dimensional co-cultures, that was abrogated by targeting leukemia inhibitory factor receptor (LIFR) in control microglia-melanoma spheroids. Altogether, these data highlight a melanoma-mediated heterogenous effect on microglial JunB expression, dictating the nature of their functional involvement in MBM progression. Targeting microglia highly expressing JunB may potentially be utilized for MBM theranostics.
Insights
Melanoma brain metastasis triggers varied microglial responses, influencing tumor progression. Targeting microglia with high JunB expression may offer new therapeutic strategies for melanoma brain metastasis.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- Reciprocal signaling between melanoma brain metastatic (MBM) cells and microglia alters their phenotypes.
- Microglia exhibit upregulated transcription factor JunB in response to MBM cells.
Purpose of the Study:
- To investigate the impact of microglial JunB upregulation on MBM progression.
- To understand the functional role of JunB in microglia-melanoma interactions.
Main Methods:
- RNA-sequencing (RNA-seq) and reverse-phase protein array (RPPA) for molecular profiling.
- Generation of microglia overexpressing (JunBhi) or downregulating (JunBlo) JunB.
- Flow cytometry and 3D co-culture models to assess microglial function and MBM cell behavior.
Main Results:
- Leukemia inhibitory factor (LIF) from melanoma cells upregulates microglial JunB via JAK/STAT3 signaling.
- JunBhi microglia show decreased migration and phagocytosis, and support melanoma cell proliferation.
- JunBlo microglia reduce melanoma proliferation and migration.
- Differential expression of microglia activation markers (Iba-1, CD150) and immunosuppressive molecules (SOCS3, PD-L1) observed in JunBhi and JunBlo cells.
Conclusions:
- Melanoma induces heterogeneous microglial JunB expression, influencing MBM progression.
- Microglia with high JunB expression support MBM growth, while those with low JunB inhibit it.
- Targeting microglia with high JunB expression presents a potential theranostic approach for MBM.
Related Concept Videos
The Tumor Microenvironment
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

